Evidence map›Paper›PMID 35662744›Full record

ArticleFuture science OA2022

Prognostic value of circulating endothelial cells in glioblastoma patients: a pilot study.

María Angeles Vaz Salgado, Julie Earl, Victor Rodriguez Berrocal, Freddy Salge Arrieta, Ana Gomez, Juan Manuel Sepulveda-Sanchez, Ángel Perez-Nuñez, Elena Corral de la Fuente, Daniel Lourido, María Villamayor and 6 more

Open access · goldAbstract read
In one paragraph

Article in Future science OA, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. A Synopsis of Biomarkers in Glioblastoma: Past and Present.Current issues in molecular biology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

María Angeles Vaz SalgadoMedical Oncology Department. Ramón y Cajal Hospital. IRYCIS, CIBERONC, Madrid, 28034, Spain.ORCID https://orcid.org/0000-0002-5913-9002
Julie EarlMedical Oncology Department. Ramón y Cajal Hospital. IRYCIS, CIBERONC, Madrid, 28034, Spain.ORCID https://orcid.org/0000-0001-9360-4716
Victor Rodriguez BerrocalNeurosurgery Department. Ramón y Cajal Hospital, Madrid, 28034, Spain.
Freddy Salge ArrietaNeurosurgery Department. Ramón y Cajal Hospital, Madrid, 28034, Spain.
Ana GomezMedical Oncology Department. Ramón y Cajal Hospital. IRYCIS, CIBERONC, Madrid, 28034, Spain.
Juan Manuel Sepulveda-SanchezMedical Oncology Department. 12 de Octubre Hospital. Instituto de Investigación I+12, Madrid, 28041, Spain.ORCID https://orcid.org/0000-0003-3548-9961
Ángel Perez-NuñezNeurosurgery Department. 12 de Octubre Hospital, Madrid, 28034, Spain.ORCID https://orcid.org/0000-0002-2391-6586
Elena Corral de la FuenteMedical Oncology Department. Ramón y Cajal Hospital. IRYCIS, CIBERONC, Madrid, 28034, Spain.
Daniel LouridoRadiology Department. Ramón y Cajal Hospital, Madrid, 28034, Spain.ORCID https://orcid.org/0000-0002-1146-4439
María VillamayorMedical Oncology Department. Ramón y Cajal Hospital. IRYCIS, CIBERONC, Madrid, 28034, Spain.
Hector PianPathology Department, Ramón y Cajal Hospital, Madrid, 28034, Spain.
Alfonso MurielClinical Biostatistic Unit, Hospital Universitario Ramón y Cajal, IRYCIS, CIBERESP, Nursing Department Universidad de Alcalá Madrid, 28034, Spain.ORCID https://orcid.org/0000-0002-4805-4011
Elisabetta RossiDepartment of Surgery, Oncology & Gastroenterology, University of Padova, Padua, 35124, Italy.ORCID https://orcid.org/0000-0003-0397-6175
Rita ZamarchiVeneto Institute of Oncology IOV - IRCCS, Padua, 35128, Italy.ORCID https://orcid.org/0000-0001-6435-2257
Alfredo CarratoMedical Oncology Department. Ramón y Cajal Hospital. IRYCIS, CIBERONC, Madrid, 28034, Spain.ORCID https://orcid.org/0000-0001-7749-8140
Luis LeyNeurosurgery Department. Ramón y Cajal Hospital, Madrid, 28034, Spain.ORCID https://orcid.org/0000-0002-4770-8271
Instituto Ramón y Cajal de Investigación Sanitaria · ESInstituto Cajal · ESResearch Institute Hospital 12 de Octubre · ESIstituto Oncologico Veneto · ITUniversidad de Alcalá · ESUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: Glioblastoma (GB) is an aggressive tumor type and the detection of circulating endothelial cells (CECs) in peripheral blood has been related to angiogenesis. Materials & methods: A prospective single-center pilot study of CEC detection at diagnosis in 22 patients with GB was performed, using the US FDA-approved CellSearch system. Results: A CEC cutoff value was estimated using a receiver operating curve (ROC) and patients were classified into two groups: <40 CEC/4 ml and >40 CEC/4 ml blood. Median overall survival was 25.33 months for group 1 and 8.23 months for group 2 cases (p = 0.02). There was no correlation between CEC and PWI (perfusion-weighted imaging) RM. Conclusion: CEC detection has a prognostic value in GB cases at diagnosis.

Indexed as

biomarkercirculating endothelial cells (CECs)glioblastomaperfusion MRI

Identifiers

PMID35662744
PMCPMC9136629
OpenAlexW4281384902

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.